Apures Co (XKRX:149300) Debt-to-Equity : 0.93 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Apures Co Debt-to-Equity?

Apures Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,610.4 Mil. Apures Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,632.0 Mil. Apures Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩6,714.0 Mil. Apures Co's debt to equity for the quarter that ended in Dec. 2023 was 0.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Apures Co's Debt-to-Equity or its related term are showing as below:

XKRX:149300' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.12 Med: 1.01 Max: 4.77
Current: 0.93

During the past 10 years, the highest Debt-to-Equity Ratio of Apures Co was 4.77. The lowest was -1.12. And the median was 1.01.

XKRX:149300's Debt-to-Equity is ranked worse than
85.13% of 195 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs XKRX:149300: 0.93

Apures Co Debt-to-Equity Historical Data

The historical data trend for Apures Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Debt-to-Equity Chart

Apures Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

4.77

-1.12

0.79

1.34

0.93

Apures Co Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					4.77	-1.12	0.79	1.34	0.93

Competitive Comparison of Apures Co's Debt-to-Equity

For the Diagnostics & Research subindustry, Apures Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apures Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Apures Co's Debt-to-Equity falls into.

Apures Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Apures Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3610.362	+	2632.019)	/	6714.026
	=	0.93

Apures Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3610.362	+	2632.019)	/	6714.026
	=	0.93

Apures Co (XKRX:149300) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Apures Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Apures Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Apures Co (XKRX:149300) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792

Website

http://www.apures.com

Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines